Key points are not available for this paper at this time.
Eli Lilly and Company has tapped Boston biotechnology firm Aktis Oncology to make new radiopharmaceuticals for solid tumors. Lilly will pay Aktis 60 million up front and up to 1. 1 billion in milestones to discover the compounds and bring them through preclinical development. Lilly will then be responsible for clinical trials and, if the drug candidates receive approval, commercialization. The companies did not disclose specific targets for the potential medicines.
Rowan Walrath (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: